ESO-T01 delivers its first four multiple myeloma case reports.
ApexOnco Front Page
Recent articles
9 July 2025
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
4 December 2024
The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.
4 December 2024
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
3 December 2024
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
3 December 2024
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
2 December 2024
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
2 December 2024
Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.